Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 27/11/2020
SIETES contiene 93167 citas

 
 
 1 a 20 de 23 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Rouse B, Cipriani A, Shi Q, Coleman AL, Dickersin K, Li T. Network meta-analysis for clinical practice guidelines: a case study, on first-line medical therapies for primary open-angle glaucoma. Ann Intern Med 2016;164:674-82. [Ref.ID 100297]
2.Tiene citas relacionadas Cita con resumen
Doshi P, Dickersin K, Healy D, Vedula SS, Jefferson T. Restoring invisible and abandoned trials: a call for people to publish the findings. BMJ 2013;346:23-6. [Ref.ID 95962]
3. Cita con resumen
Chan A-W, Telzlaff JM, Altman DG, Laupacis A, Gotzche PC, Krieza-Jeric K, Hrobjartsson A, Mann H, Dickersin K, Berlin JA, Doré CJ, Parulekar WR, Summerskill WSM, Groves T, Schulz KF, Sox HC, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med 2013;158:200-7. [Ref.ID 94901]
4. Cita con resumen
Chan AW, Tetzlaff JM, Altman DG, Dickersin K, Moher D. SPIRIT 2013: new guidance for content of clinical trial protocols. Lancet 2013;381:91-2. [Ref.ID 94763]
6.Tiene citas relacionadas
Dickersin K, Rennie D. The evolution of trial registries and their use to assess the clinical trial enterprise. JAMA 2012;307:1861-4. [Ref.ID 92858]
8.Tiene citas relacionadas
Goodman S, Dickersin K. Metabias: a challenge for comparative effectiveness research. Ann Intern Med 2011;155:61-2. [Ref.ID 91364]
9.Tiene citas relacionadas Cita con resumen
Vedula SS, Dickersin K. Reporting of trials of gabapentin. The authors reply. N Engl J Med 2010;362:1641-2. [Ref.ID 88354]
10.Tiene citas relacionadas Cita con resumen
Vedula SS, Bero L, Scherer RW, Dickersin K. Outcome reporting in industry-sponsored trials of gabapentin for off-label use. N Engl J Med 2009;361:1963-71. [Ref.ID 87221]
11.Tiene citas relacionadas Cita con resumen
Gülmezoglu AM, Pang T, Horton R, Dickersin K. WHO facilitates international collaboration in setting standards for clinical trial registration. Lancet 2005;365:1829-31. [Ref.ID 73984]
12.Tiene citas relacionadas Cita con resumen
Krleza-Jeric K, Chan AW, Dickersin K, Sim I, Grimshaw J, Gluud C, for the Ottawa Group. Principles for international registration of protocol information and results from human trials of health related interventions: Ottawa statement (part 1). BMJ 2005;330:956-9. [Ref.ID 73546]
13. Cita con resumen
Dickersin K, Goodman S. The long and creative arm of the drug industry. Lancet 2005;365:656. [Ref.ID 72891]
14.Tiene citas relacionadas Cita con resumen
Dickersin K, Rennie D. Registering clinical trials. JAMA 2003;290:516-23. [Ref.ID 66992]
15.Tiene citas relacionadas
Dickersin K, Olson CM, Rennie D, Cook D, Flanagin A, Zhu Q, Reiling J, Pace B. Association between time interval to publication and statistical significance. JAMA 2002;287:2829-31. [Ref.ID 62366]
16.Tiene citas relacionadas Cita con resumen
Olson CM, Rennie D, Cook D, Dickersin K, Flanagin A, Hogan JW, Zhu Q, Reiling J, Pace B. Publication bias in editorial decision making. JAMA 2002;287:2825-8. [Ref.ID 62365]
17.
Dickersin K, Scherer R, Suci EST, Gil-Montero M. Problems with indexing and citation of articles with group authorship. JAMA 2002;287:2772-4. [Ref.ID 62347]
18.Tiene citas relacionadas Cita con resumen
Dickersin K. Breast screening in women aged 40-49 years: what next?. Lancet 1999;353:1896-7. [Ref.ID 44824]
19.
Dickersin K, Fredman L, Flegal KM, Scott JD, Crawley B. Is there a sex bias in choosing editors? Epidemiology journals as an example. JAMA 1998;280:260-4. [Ref.ID 39398]
20.
Dickersin K, Berlin JA. Meta-analysis: state-of-the-science. Epidemiol Rev 1992;14:154-76. [Ref.ID 19049]
Seleccionar todas
 
 1 a 20 de 23 siguiente >>